NEW YORK (GenomeWeb) – T2 Biosystems announced after the close of the market today that it has begun a public offering of 3.5 million shares of its common stock.

The company also said it expects to grant the underwriters of the offering a 30-day option to buy an additional 525,000 shares at the public offering price. Goldman Sachs is acting as the book-running manager for the offering. Additional underwriters include Leerink Partners, Canaccord Genuity, and Cantor Fitzgerald.

T2's stock closed at $11.77 in Tuesday trade on the Nasdaq.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.